Biomea Fusion (BMEA) Corporate presentation summary

Strategic vision and market opportunity

• Focused on transforming diabetes and obesity treatment with novel oral medicines targeting beta cell restoration and improved weight management.

• Addressing large unmet needs in diabetes and obesity, with over 38 million people living with diabetes and 190 million obese or overweight in the U.S.

• Diabetes represents a significant economic burden, accounting for 25% of U.S. healthcare spending.

• Current therapies often fail to address the root cause of diabetes or have high discontinuation rates due to side effects.

Pipeline and clinical programs

• Advancing two differentiated programs: icovamenib (oral menin inhibitor) and BMF-650 (next-generation oral GLP-1 receptor agonist).

• Icovamenib targets beta cell restoration for both type 1 and type 2 diabetes, aiming to delay insulin dependence and reduce complications.

• BMF-650 is designed for improved tolerability, higher bioavailability, and scalable weight reduction in obesity and diabetes.

• Multiple Phase II readouts are anticipated over the next 12 months, with cash runway into 1Q 2027.

Icovamenib mechanism and preclinical data

• Icovamenib selectively reduces menin levels, promoting beta cell proliferation and enhancing GLP-1 receptor expression.

• Preclinical models show significant reductions in blood glucose, increased insulin secretion, and preservation of lean mass.

• Demonstrated synergistic effects with GLP-1 therapies, leading to improved glycemic control and greater weight loss.

• Promoted lipolysis and fat browning in adipocytes, supporting potential for weight management.